Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

564
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
564
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

347
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
347
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

705
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
705
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

347
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
347
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

336
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
336

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolically healthy obesity is independently associated with 20-year incidence of cardiovascular disease: findings from the ATTICA cohort study (2002-2022).

International journal of obesity (2005)·2026
Same author

Prediabetes and 20-year cardiovascular disease incidence: the ATTICA cohort study (2002-2022).

European journal of preventive cardiology·2026
Same author

One-Hour Post-Load Glucose Is Associated with Multisystem Complications in People Living with Obesity.

Biomolecules·2026
Same author

Lipoprotein (a) levels are elevated in psoriasis: An updated systematic review and meta-analysis.

World journal of clinical cases·2025
Same author

Vitamin B12 deficiency among older adults and its associations with geriatric syndromes.

Current opinion in clinical nutrition and metabolic care·2025
Same author

Does statin matter when it comes to Lipoprotein(a) levels?

Atherosclerosis·2025

Related Experiment Video

Updated: Apr 7, 2026

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
06:50

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Published on: September 5, 2025

614

Safety considerations with fenofibrate/simvastatin combination.

Theodosios D Filippatos1, Moses S Elisaf

  • 1a 1 University of Ioannina, School of Medicine, Department of Internal Medicine , 45 110 Ioannina, Greece.

Expert Opinion on Drug Safety
|July 3, 2015
PubMed
Summary

The combination of fenofibrate and simvastatin is generally safe for mixed dyslipidemia, with no significant increase in serious adverse events compared to simvastatin alone. The risk of rhabdomyolysis is very low.

Keywords:
adverse effectscardiovascular diseasedrug interactionsfenofibratemixed dyslipidemiapharmacokineticssafetysimvastatintolerability

More Related Videos

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.9K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Related Experiment Videos

Last Updated: Apr 7, 2026

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening
06:50

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Published on: September 5, 2025

614
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.9K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Mixed dyslipidemia management often involves combination therapy.
  • Fenofibrate and simvastatin are commonly prescribed lipid-lowering agents.
  • Assessing the safety of combined fenofibrate/simvastatin is crucial for clinical practice.

Purpose of the Study:

  • To critically review the safety profile of fenofibrate/simvastatin combination therapy.
  • To evaluate adverse events associated with this combination based on robust clinical evidence.
  • To provide an expert opinion on the risk-benefit ratio of fenofibrate/simvastatin.

Main Methods:

  • Systematic review of large randomized controlled trials (RCTs) and relevant studies.
  • Analysis of clinical pharmacology and drug interaction data.
  • Evaluation of effects on metabolic variables and cardiovascular risk.

Main Results:

  • Large RCTs indicate no significant increase in serious adverse events versus simvastatin monotherapy.
  • A slight, but very low, increased incidence of rhabdomyolysis observed with combination therapy.
  • No significant increase in diabetic nephropathy or thrombotic events in ACCORD Lipid trial; fenofibrate showed decreased albuminuria in FIELD and ACCORD Lipid trials.

Conclusions:

  • Fenofibrate/simvastatin combination demonstrates a favorable safety profile in large clinical trials.
  • The combination is considered safe when prescribed appropriately, avoiding patients with predisposing risk factors for adverse events.
  • Careful patient selection is essential to maximize the benefits and minimize risks of fenofibrate/simvastatin therapy.